Recorded third quarter 2025 worldwide revenue of $384.0 million, GAAP fully diluted earnings per share of$0.41, adjusted fully diluted earnings per share of $1.27 and free cash flow of$94.7 millionSeparately announced upcoming retirement of CEO, departure of President and appointment of prior CEO to Executive Chairperson; Board conducting CEO searchAnnounced PDUFA dates for its new formulation of piflufolastat F 18 PSMA PET imaging agent; for MK-6240, its F 18 tau-targeted positron emission tomography (PE ...